February 2019 Issue Vol. 4(1), pp. 001-009
Copyright © 2019 Transcontinental Publishers
Full Length Research Paper
Registry on Monitoring the Effectiveness and Tolerability of Basal (Plus/Bolus) Regimen with Insulin Glargine and Insulin Glulisine in T2 Diabetes Mellitus Patients in Everyday Practice in Saudi
Nasser Al Juhani1*, Ezzat Karima2, Amani El Hozali3, Rashid AL JAWAIR4, Ashraf Shaaban5, Hossam Dessouky6, Nevine Abdulfattah7 and Roquyia Abdellah7
1Al Sharq General Hospital, Jeddah, Kingdom of Saudi Arabia
2Hai Al Jamaa Hospital, Jeddah, Kingdom of Saudi Arabia
3King Abdul Aziz University Hospital, Kingdom of Saudi Arabia
4King Fahad Military Medical Complex, Dammam, Kingdom of Saudi Arabia
5Ghassan Pheroun Hospital, Jeddah, Kingdom of Saudi Arabia
6United Doctors Hospital, Jeddah, Kingdom of Saudi Arabia
7Armed Forces Hospital, Khamis Mesheet, Kingdom of Saudi Arabia
*Corresponding Author E-mail: firstname.lastname@example.org; +966566987788
Accepted 19 February, 2019
Type 2 Diabetes Mellitus (T2DM) has emerged as a major global health problem and is one of the most common chronic diseases worldwide. The prevalence of T2DM in Kingdom of Saudi Arabia (KSA) population is high (23%) and has increased by 10% in just one decade. Usually addition of basal insulin is considered as the simplest way to start insulin therapy in patients uncontrolled on oral antidiabetic agents (OADs). In KSA, the majority of patients(60%) recommended to use insulin are treated with premixed insulin.Currently there is limited availability of local (KSA) data documenting the switch from premixed insulin to a basal insulin (Plus/Bolus) regimen. To monitor the effectiveness and tolerability of basal (Plus/Bolus) using Insulin glargine and Insuline glulisine in T2DM patients switched from premixed insulin for achieving the glycemic goal (Glycatedhaemoglobin - HbA1c) as targeted by the treating physician. Multicenter, non-interventional prospective product registry was conducted nationwide across KSA. Males and females aged ≥ 21 years, with type 2 diabetes mellitus, uncontrolled on premixed insulin with HbA1C>7 % and Fasting Blood Sugar >120 mg/dL were selected for this study. Changes in HbA1C from baseline to the end of 6 months and the mean number of hypoglycemic episodes experienced by each patient were measured. Out of 619 enrolled patients, 543 patients completed all study visits. There was statistically significant mean change in HbA1c (2.02%) at visit 3 as compared to baseline. Forty-three percent reduction in hypoglycemia incidence (number of patients experiencing at least one hypoglycemic event) and a 30% reduction in event rate from base line till end of 6 months was also seen in this study. In everyday clinical practice, patients with type 2 diabetes inadequately controlled on premixed insulins experienced significant improvements in glycemic control over 24 weeks after switching to a glargine-based insulin regimen. There was also a significantly lower risk of hypoglycemia and a favorable tolerability profile with this regimen. These findings support the use of a basal-bolus glarginebased regimen in T2DM patients poorly controlled on premixed insulins in KSA.
Keywords: T2DM, Insulin Glargine, Insulin Glulisine, KSA, registry.
Cite this Reference
Nasser Al Juhani, Ezzat Karima, Amani El Hozali, Rashid AL JAWAIR, Ashraf Shaaban, Hossam Dessouky, Nevine Abdulfattah and Roquyia Abdellah (2019). Registry on Monitoring the Effectiveness and Tolerability of Basal (Plus/Bolus) Regimen with Insulin Glargine and Insulin Glulisine in T2 Diabetes Mellitus Patients in Everyday Practice in Saudi. Interlink Continental J. Med. Med. Sci. 4(1): 001-009.
Al-Daghri N, Al-Attas O, Alokail M, et al (2011). Diabetes mellitus type 2 and other chronic non-communicable diseases in the central region, Saudi Arabia, a decade of an epidemic, BMC Medicine. 9:76. doi: 10.1186/1741-7015-9-76.
American Diabetes Association (2009). Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 32(1):S62-S67. doi:10.2337/dc09-S062.
Ampudia-Blasco F, Rossetti P, Ascaso J (2011). Basal plus basal-bolus approach in type 2 diabetes. Diabetes Technol Ther. 13(1):S75-83. doi: 10.1089/dia.2011.0001.
Bagust A, Beale S (2009). Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM. 96(4):281-288.
Benson K, Hartz A (2000). A comparison of observational studies and randomized, controlled trials. NEJM. 342:1878-1886.
Cerf ME (2013). Beta Cell Dysfunction and Insulin Resistance. Frontiers in Endocrinology. 4:37. doi:10.3389/fendo.2013.00037.
Davies M, Sinnassamy P, Storms F, et al (2008). Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Res Clin Pract. 79:368-375.
Gumprecht J, Benroubi M, Borzi V, et al (2009). Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study Int J Clin Pract. 63(6):966-972.
Hammer H, Klinge A (2007). Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. Int J Clin Pract. 61:2009-2018.
Herman W, Liza L, Susan L, et al (2005). A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes Diabetes Care. 28(7): 1568-1573.
Helsinki declaration (1964). WMA declaration of Helsinki. Ethical principles for medical research.
Home P, Mant J, Diaz J, et al (2008). Turner Management of type 2 diabetes: summary of updated NICE guidance. BMJ, 336(7656):1306-1308.
Huxley R, Barzi F, Woodward M (2006). Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. Br. Med. J. 2006; 332:73-78.
Jang H, Guler S, Shestakova M (2008). When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the present study Int. J. Clin. Pract. 62(7):1013–1018.
Kanatsuka A, Kawai K, Hirao K, et al (2012). Japan Diabetes Clinical Data Management Study Group. The initiation of insulin therapy in type 2 diabetic patients treated with oral anti-diabetic drugs: an observational study in multiple institutes across Japan (JDDM27) Diabetol Int, 3(3): 164-173.9.
KSU data: Insulin prescribing practice in Saudi Arabia. http://faculty.ksu.edu.sa/70171/Documents/P2.pdf, Saudi patients’ flow data (IMS and Tender Data)
Lankisch M, Ferlinz K, Leahy J, et al (2008). Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs Diabetes Obes. Metabol. 10(12):1178–1185.
Lasserson D, Glasziou P, Perera R, et al (2009). Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses Diabetologia, 52(10):1990–2000.
Levin P, Zhang Q, Mersey J, et al (2011). Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design. Clin. Ther. 33(7):841-850.
Mastura I, Chew B, Lee P (2011). Control and treatment profiles of 70,889 adult type 2 diabetes mellitus patients in Malaysia-a cross sectional survey in 2009. Int. J. Collab. Res. Intern. Med. Public Health. 3(1): 98–113.
MEMS - Malaysian Endocrine and Metabolic Society (2011). Practical guide to insulin therapy in type 2 diabetes mellitus.
Monnier L, Colette C, Dunseath G, et al (2007). The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 30:263–269.
Monnier L, Colette C (2006). Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities Diabetes Metabol. 32(1): 7-13.
Nathan D, Buse J, Davidson M, et al (2009). Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the ADA/EASD. Diabetes Care. 32(1):193-203
Raccah D, Bretzel R, Owens D, et al (2007). When basal insulin therapy in type 2 diabetes mellitus is not enough—what next? Diabetes Metabol Res. Rev. 23(4): 257-264.
Riddle M (2005). Making the transition from oral to insulin therapy Am. J. Med. 118 (5):14–20.
Rosenstock J, Ahmann A, Colon G, et al (2008). Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents prandial premixed (insulin lispro protamine suspension / lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 31(1):20–25.
Rosenstock J, Dailey G, Massi-Benedetti M, et al (2005). Reduced hypoglycemia risk with insulin glargine. A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 28(4):950-955.
Schiel R, Muller U (2007). Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study. Exp. Clin. Endocrinol Diabetes. 115:627-633.
Stolar M (2010). Glycemic control and complications in type 2 diabetes mellitus. Am. J. Med. 2010. 123:S3–S11. doi: 10.1016/j.amjmed.2009.12.004.
Stratton I, Adler A, Neil H, et al (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ. 12; 321(7258):405-412.
Stumvoll M, Goldstein B, Haeften T (2005). Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 365: 1333–46
Turnbull F, Abraira C, Anderson R, et al (2009). Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 52:2288-2298.
Rosenstock J, Ahmann AJ, Colon G, et al (2008). Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/ bolus (glargine/lispro) therapy. Diabetes Care. 31:20-25.